@article{GS600,
author = {Petrelli Fausto and Sandro Barni},
title = {Benefit of tamoxifen in estrogen receptor positive DCIS of the breast},
journal = {Gland Surgery},
volume = {1},
number = {1},
year = {2012},
keywords = {},
abstract = {Allred and colleagues recently published, in Journal of Clinical Oncology, a retrospective analysis which illustrates the benefits of tamoxifen (TAM) in ductal carcinoma in situ (DCIS) according to the estrogen receptor (ER) status (1). The analysis included 41% of the original sample of the NSABP24 trial (2). TAM reduced the hazard of relapse by 50% at 10 years of follow-up among 76% patients resulting ER+ in this trial. No benefit was observed in ER-patients with DCIS. The strength of this analysis was the centralisation of receptor analysis, in the majority of cases, according to standard immunohistochemical analysis.},
issn = {2227-8575}, url = {https://gs.amegroups.org/article/view/600}
}